Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Desamax, what did you ask them? Did they answer your question? I thought it was in relation to the amount of trials waiting on MHRA.
Let's not forget that the COVID route to market had a prerequisite of a clinical stage compound, we're now a clinical stage compound. I'd imagine this has fallen away somewhat now though.
Interested to hear Tim and John comment on this at next meeting.
They did have $574million in cash at end of 2022 though.
This is where Sareum need to decide are we sticking to the business model or playing with the big boys. It would be a complete restructure so I'm certain we will license 1801 before the end of phase 1. As already mentioned, the longer it is left the more they will have to pay, price now and the price and interest after 1b will be very different.
Once our cash position is secured to end of phase 1 then the SP will be released, how good are those investor relationships is the question. We certainly don't want a market placing or another investor for that matter. Unless we are dreaming big. Who knows all guess work at the minute.
Certainly a good time to have something of value in the autoimmune space.
The short answer on SRA737 imo, other chk1 compound's have had many failures and discontinuations over the last 10years, that's why some drugs just takes years to get to market, further clinical research by CRUK helps promote it, and we have a spokesman in CRUK for SRA737. So it is a matter of time until that progresses, as always. It costs us nothing and we have everything to gain, 1801 is the focus though, as previously mentioned, it's a biotech company on its own.
The relationships Parker and Peel have built over the last few years will be progressing now that we are in the clinic. Funding RNS would give the confidence to move this to the next level. I'm sure it's being discussed and hopefully hear something within the next few weeks.
I had the pleasure to talk to Thoth personally on a number of occasions and often exchanged whattsApp messages. Great guy with a true desire to help his fellow citizens. He gave me lots of practical advice over the years and we both had a true belief that what Tim and Co have is a once in a lifetime opportunity, unfortunately his worst fear came true and that it wouldn't be within his lifetime.
Just makes us all think about how we need to live for today and enjoy what time we have.
I'm very pleased to hear he had his daughters at his side, those days at the races will be treasured for a long time. Hopefully the name Richard H. has been involved with getting everything sorted for you/them as he was the only person Thoth trusted with money and investments.
Look forward to the £14 party in honour of Thoth!
Want to know why we really went to OZ...
https://www.gov.uk/government/publications/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review/commercial-clinical-trials-in-the-uk-the-lord-oshaughnessy-review-final-report#part-2-problem-statements-and-significant-actions
Scathing report. At least change will be on the horizon for SDC1802.
Going to post a few links here's to put into perspective what we have with SDC-1801 alone. For those that don't want to look through it all, the short summary is, SDC-1801 is a pharma company on its own.
Best read in order below.
https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01397 (compound 6 is the focus) brepocitinib
https://www.evaluate.com/vantage/articles/news/snippets/pfizer-bows-out-tyk2-race
https://www.pfizer.com/news/press-release/press-release-detail/roivant-and-pfizer-unveil-priovant-therapeutics-and-ongoing
https://www.priovanttx.com/pipeline.html
And lastly to wrap to all up. Think about the manpower of Sareum, 2 directors, a chairman and 2 NEDS, now look at this manpower for another tyk2/jak1 ONLY company;
https://www.priovanttx.com/about.html
Perspective. Hand on to these people. You'll not get another opportunity like this.
Https://www.fiercebiotech.com/biotech/bicycle-rides-second-17b-big-pharma-deal-two-months-time-bayer
SKIL platform value is something often overlooked, yet it has produced our tyks and aurora+flt3. With many more in discovery mode. Further strings to the Sareum bow which should make its way into broker valuation figures over the next 12months.
Disappointed with the share price after that pivotal RNS, lack of interest now that funds have been mentioned. Maybe a repeat of summer 2021 on the cards though.
An old published debate between Tim and Don Nicholson on tyk2.
https://www.google.com/url?sa=t&source=web&rct=j&url=http://www.nimbustx.com/wp-content/uploads/2017/10/BioCentury-Innovations-Nimble-Move-10.5.2017.pdf&ved=2ahUKEwii8q2P4uP-AhXhU6QEHeg6BP4QFnoECAsQAQ&usg=AOvVaw1CgUqdpX922rXZ_xtPQw5k
Sareum have been very clear on the strategy, license pre or early clinical. I believe they will have a number of interested parties awaiting the first in human safety data.
Either they license the single compound or the company gets bought out. It's a great time to be invested and the tyk2 market is emerging as a valid therapeutic target with some big figures for sales estimated.
Importantly, we clearly differentiate from existing compounds being tyk2 only. Only time will tell if we improve on efficacy, the science says we will for psoriasis due to dual inhibition.
Not long to go.
Paves the way for the license now, how many big pharma will want something that can compete with BMS and Takeda..Parker going to be busy this year. This should have the HNWI lined up for the extra funding for 1b, sniff of positive 1a and bank roll this until the license.
Doors are being opened on multiple fronts.
Hi Andy, I'm good mate, looking forward to the next few months as Sareum have a real opportunity to manage the SP in the interest of shareholders.
Although part 4 doesn't have a PASI score as a primary outcome they are requiring participants to "4. Has moderate to severe plaque psoriasis at baseline as defined by a PASI score greater than or equal to 10 and a PGA score greater than or equal to 3 at Screening and Day -1."
It feels they have really set themselves up for success, they have the ability to report on primary and secondary outcomes at each stage of the trail, of which we have 4, 2 and 3 can run concurrently so we should expect a healthy stream of positive news from any day now, until next year.
So many string to the bow and we are really looking like a clinical stage company now. Except the number of personnel and overheads. Which makes a full buyout extremely efficient. One something is agreed I don't expect it to take long to filter through the company, of 3.
I'm sure Australia would also jump on the covid-19 application of SDC-1801 once proven safe.
Looking forward to seeing these big daily increases again.
Just reigniting this thread. A more important and final trial is also available to view with some interesting insights which may tell you the thought process of the board:
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=385667&isReview=true
"Part 4 of this study will have a randomised, double-blind design, and consist of 2 sequential dose cohorts (Cohorts Psoriasis Dose i and Psoriasis Dose ii). Each cohort will consist of 12 participants with moderate to severe plaque psoriasis."
Yes, 12 participants in each cohort.
"Each participant will be in the study for approximately 8 weeks (Screening Visit to Follow-up Visit) and will receive a maximum of 14 or 27 doses of SDC-1801 or placebo."
Either we don't have enough money to run a larger trial or we don't really need to due to expected license already pre-agreed based on parts 1/2/3 being a success.
I don't think we would take on such a low amount of participants based on lack of funds, the company has come this far and in my opinion if they thought they needed 50/60 participants to get this over the line then I am confident that is the route they would have taken. Having only 12 in each cohort for 8 weeks shows a level of confidence for the future of the compound imo. Perhaps they won't even get that far and once safety data confirmed and it moves through parts 1-3, the license comes with a larger phase I/II by someone else.
Great find HBD. Hopefully we made the timeline for HREC in April.
Doesn't seem like they have used the previously mentioned phase 1a and b. More phase 1. Then split to 2 parts. As it also states it wants psoriasis patients.
This is when I believe we will see further high net worth investors provide the funding, when it's in clinic the next stage for us is a buyout / license. Sooner you get in the better, HNW will be happy with the current share price and I suspect further millions coming our way as they take positions to support this compound. They know the end potential now, $4 billion at phase 2, Nimbus. Got to be back up to 400milliom market cap in the next month or 2.
GLA.
No doubt out existing investors are speaking to Tim and Stephen about this progress and the level of assurance they can provide with approval of these trials in Australia.
As mentioned refusal again would destroy us, but John gave a very confident statement at AGM that we will not have the same problem as we had with MHRA.
It's an absolute disaster for the UK though, from being ready to go at Manchester to now transfering to Australia. Does this mean we are a multinational now, having an entity in Oz. Haha.
And it's stories like this that Sierra Oncology should be taken to a form of Medical ethics council, as well as the CRT Pioneer Fund for not applying enough pressure. A criminal offence in lots of peoples eyes letting this sit and gather dust. Best wishes to you potnak and your family.